164 related articles for article (PubMed ID: 18498377)
1. Cutaneous infection with Leishmania infantum in an infant treated successfully with miltefosine.
Neub A; Krahl D; Stich A; Amon U
J Dtsch Dermatol Ges; 2008 Dec; 6(12):1061-4. PubMed ID: 18498377
[TBL] [Abstract][Full Text] [Related]
2. Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA.
de Vries PJ; van der Meide WF; Godfried MH; Schallig HD; Dinant HJ; Faber WR
Trans R Soc Trop Med Hyg; 2006 Dec; 100(12):1183-6. PubMed ID: 16678871
[TBL] [Abstract][Full Text] [Related]
3. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
Aguiar MG; Silva DL; Nunan FA; Nunan EA; Fernandes AP; Ferreira LA
J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819
[TBL] [Abstract][Full Text] [Related]
4. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis.
Sundar S; Jha TK; Sindermann H; Junge K; Bachmann P; Berman J
Pediatr Infect Dis J; 2003 May; 22(5):434-8. PubMed ID: 12792385
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of imported mucosal Leishmania infantum leishmaniasis with miltefosine after severe hypokalemia under meglumine antimoniate treatment.
Neumayr AL; Walter C; Stoeckle M; Braendle N; Glatz K; Blum JA
J Travel Med; 2012; 19(2):124-6. PubMed ID: 22414039
[TBL] [Abstract][Full Text] [Related]
6. Natural Resistance of
Carnielli JBT; Monti-Rocha R; Costa DL; Molina Sesana A; Pansini LNN; Segatto M; Mottram JC; Costa CHN; Carvalho SFG; Dietze R
Am J Trop Med Hyg; 2019 Oct; 101(4):789-794. PubMed ID: 31436148
[TBL] [Abstract][Full Text] [Related]
7. Serial use of pentamidine and miltefosine for treating Leishmania infantum-HIV coinfection.
Faucher JF; Morquin D; Reynes J; Chirouze C; Hoen B; Le Moing V
Parasitol Int; 2016 Oct; 65(5 Pt A):444-6. PubMed ID: 27353022
[TBL] [Abstract][Full Text] [Related]
8. [Miltefosine: a new remedy for leishmaniasis].
Dorlo TP; Eggelte TA; Beijnen JH; de Vries PJ
Ned Tijdschr Geneeskd; 2006 Dec; 150(49):2697-701. PubMed ID: 17194005
[TBL] [Abstract][Full Text] [Related]
9. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.
Calvopina M; Gomez EA; Sindermann H; Cooper PJ; Hashiguchi Y
Am J Trop Med Hyg; 2006 Dec; 75(6):1074-7. PubMed ID: 17172368
[TBL] [Abstract][Full Text] [Related]
10. Leishmania DNA quantification by real-time PCR in naturally infected dogs treated with miltefosine.
Manna L; Gravino AE; Picillo E; Decaro N; Buonavoglia C
Ann N Y Acad Sci; 2008 Dec; 1149():358-60. PubMed ID: 19120249
[TBL] [Abstract][Full Text] [Related]
11. First case of typical Old World cutaneous leishmaniasis treated with miltefosine.
Stojkovic M; Junghanss T; Krause E; Davidson RN
Int J Dermatol; 2007 Apr; 46(4):385-7. PubMed ID: 17442078
[TBL] [Abstract][Full Text] [Related]
12. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
Sundar S; Rai M; Chakravarty J; Agarwal D; Agrawal N; Vaillant M; Olliaro P; Murray HW
Clin Infect Dis; 2008 Oct; 47(8):1000-6. PubMed ID: 18781879
[TBL] [Abstract][Full Text] [Related]
13. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
Sundar S; Kumar K; Chakravarty J; Agrawal D; Agrawal S; Chhabra A; Singh V
Trans R Soc Trop Med Hyg; 2006 Jul; 100(7):698-700. PubMed ID: 16325873
[TBL] [Abstract][Full Text] [Related]
14. First report of Leishmania infantum infection in the endangered orangutan (Pongo pygmaeus pygmaeus) in Madrid, Spain.
Miró G; Troyano A; Montoya A; Fariñas F; Fermín ML; Flores L; Rojo C; Checa R; Gálvez R; Marino V; Fragío C; Martínez-Nevado E
Parasit Vectors; 2018 Mar; 11(1):185. PubMed ID: 29554944
[TBL] [Abstract][Full Text] [Related]
15. Nodular lymphangitic subcutaneous dissemination after intralesional antimonial treatment for localized cutaneous leishmaniasis.
Yébenes M; Cruz I; Cañavate C; Gilaberte M; Baena V; Pujol RM
Clin Exp Dermatol; 2008 Mar; 33(2):142-4. PubMed ID: 18076691
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.
Soto J; Rea J; Balderrama M; Toledo J; Soto P; Valda L; Berman JD
Am J Trop Med Hyg; 2008 Feb; 78(2):210-1. PubMed ID: 18256415
[TBL] [Abstract][Full Text] [Related]
17. New insights with miltefosine unresponsiveness in Brazilian Leishmania infantum isolates.
Bhattacharya A; Ouellette M
EBioMedicine; 2018 Nov; 37():13-14. PubMed ID: 30314891
[No Abstract] [Full Text] [Related]
18. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
Croft SL; Engel J
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
[TBL] [Abstract][Full Text] [Related]
19. Molecular detection of infection homogeneity and impact of miltefosine treatment in a Syrian golden hamster model of Leishmania donovani and L. infantum visceral leishmaniasis.
Eberhardt E; Mondelaers A; Hendrickx S; Van den Kerkhof M; Maes L; Caljon G
Parasitol Res; 2016 Oct; 115(10):4061-70. PubMed ID: 27412759
[TBL] [Abstract][Full Text] [Related]
20. Identification of a Leishmania infantum gene mediating resistance to miltefosine and SbIII.
Choudhury K; Zander D; Kube M; Reinhardt R; Clos J
Int J Parasitol; 2008 Oct; 38(12):1411-23. PubMed ID: 18457839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]